HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy

Background: Zoledronic acid as bisphosphonates could increase bone mineral density (BMD), which in osteogenesis imperfecta will reduce clinical manifestations. Pediatric patients with osteogenesis imperfecta given zoledronic acid therapy should improve their quality of life.Methods: A retrospective analytic study was conducted on 16 pediatric osteogenesis imperfecta patients who had received intravenous zoledronic acid. Interview using PedsQL 4.0 regarding the condition before and after therapy assessed the quality of life. A paired t-test was used to assess the contrast in each aspect of PedsQL 4.0. Results were expressed as an adjusted odds ratio with a 95% confidence interval. P-value <0.05 is considered statistically significant.Results: A significant increase was found in the child report of social performance (+12.083, p=0.023), and proxy report of physical performance, social performance, and total score of the proxy report (+14.844, p=0.006; +10.625, p=0.010; +10.364, p=0.006). An insignificant increase was found in the child report of physical performance, school performance, and total score of the child report (+8.833, p=0.148; +5.000, p=0.359; +7.065, p=0.115), and proxy report of emotional performance and school performance (+2.500, p=0.669; +6.250, p=0.167). An insignificant decrease was found in child reports of emotional performance (-2.500, p=0.669).Conclusion: After receiving bisphosphonate therapy, pediatric patients with osteogenesis imperfecta experienced an increased quality of life in most aspects within every perception. Physical and social aspects experienced the greatest improvement. Emotional is the aspect that experienced the lowest increase in the child's perception and decreased parent perception of the value of quality of life after bisphosphonate therapy.